Peptide Profile
Ovagen
Hepatoprotective tripeptide bioregulator (Glu-Asp-Leu) that penetrates hepatocyte nuclei to bind DNA in the minor groove at AT-rich promoter regions, upregulates antioxidant enzymes (SOD, glutathione peroxidase, GST) beyond melatonin's capacity, and supports liver regeneration through epigenetic activation of hepatocyte proliferation and anti-fibrotic gene programs
Dose Range
10-20mg
Frequency
Multiple times daily
Route
Oral (capsule — standard formulation)
Cycle Length
8-12 weeks
Onset
Gradual (3-4 weeks)
Evidence
Limited
Compound Profile
Scientific & Efficacy Data
C15H25N3O8
Molecular Formula
375.4 g/mol
Molecular Weight
Short plasma half-life typical of tripeptides; biological effects persist for weeks through epigenetic modifications to hepatic gene expression; metabolized to constituent amino acids (glutamic acid, aspartic acid, leucine)
Half-Life
Effective via oral capsule (10 mg twice daily), sublingual liquid (0.1 mg/mL), and subcutaneous injection routes; penetrates cell membranes and nuclear membranes as a cell-penetrating peptide; tissue-specific activity demonstrated in organotypic hepatic cultures at 10⁻⁶ to 10⁻⁹ M
Bioavailability
Not assigned (proprietary Khavinson peptide)
CAS #
444128
PubChem ID ↗
Developed By · 2000s (part of Khavinson's systematic peptide bioregulator research program)
American BioScience Inc.
American BioScience Inc.
Primary Benefits
Provides genuine geroprotective hepatoprotection with significantly greater effects in aged organisms — restoring age-declined liver function through epigenetic gene regulation, antioxidant enzyme upregulation (SOD, glutathione peroxidase, GST), and hepatocyte regenerative capacity that specifically counteracts the progressive hepatic deterioration of aging
Supports liver regeneration and recovery through stimulation of hepatocyte proliferation, reduction of fibrosis progression, protection against hepatitis-induced damage, and accelerated hepatic mass recovery after injury — demonstrated in partial hepatectomy models and hepatitis experimental systems
Supports hepatic metabolic function through enhanced protein synthesis capacity, normalized liver enzyme parameters, improved hepatic detoxification pathways, and restoration of metabolic homeostasis — with the liver serving as the central metabolic organ affected by aging
Amino Acid Sequence
GYPSSK-GGGGL-GGGGLDosing
How much
do I take?
Starting Dose
1 capsule (10 mg) once daily
Conservative oral protocol using the standard capsule formulation. Take 15-30 minutes before meals for optimal absorption. Alternatively, sublingual liquid (5-6 drops, 3-4 times daily) provides faster absorption. Effects are gradual — hepatoprotective gene activation builds over the treatment course. Monitor liver function parameters if available.
Standard Dose
1 capsule (10 mg) twice daily or sublingual 5-6 drops 3-4 times daily
Standard Khavinson protocol providing a total course dose of 100-200 mg over 10 days. Sublingual formulation provides 0.1 mg peptide/mL with 5-6 drops administered 10-15 minutes before meals. Repeat courses every 3-6 months. Can be combined with Livagen for comprehensive liver bioregulation. Hepatoprotective gene programs activate during the course and persist beyond treatment.
Advanced Dose
10 mg twice daily (oral) or 2-8 mcg/kg subcutaneously
Extended protocol for individuals with significant age-related hepatic decline or recovering from liver disease. Injectable route provides more predictable bioavailability. Often combined with Livagen for dual-peptide liver support and Epithalon for comprehensive anti-aging. The 266-person clinical study used peptide courses annually over 6-8 years with cumulative benefits. Medical supervision recommended.
Timing
Best time to take
Take Ovagen at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
Ovagen can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
Ovagen should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Supporting liver function and hepatoprotection in aging individuals
Ovagen is particularly well-suited for individuals focused on supporting liver function and hepatoprotection in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting hepatic aging and metabolic health
Ovagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting hepatic aging and metabolic health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery support after hepatic injury or liver disease
Ovagen is particularly well-suited for individuals focused on recovery support after hepatic injury or liver disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy for maintaining liver regenerative capacity during aging
Ovagen is particularly well-suited for individuals focused on geroprotective therapy for maintaining liver regenerative capacity during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, leucine)
- ×Pregnancy and breastfeeding — insufficient reproductive safety data
- ×Severe glutamic acid metabolism disorders (extremely rare)
- ×Active autoimmune hepatitis in flare without physician supervision
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Ovagen use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Ovagen in its prescribed form
- •Clean, dry storage container
- •Measuring device if applicable (oral syringe, measuring cup)
- •Calendar or reminder app for dosing schedule
Injection
Route
Ovagen is administered Oral (capsule — standard formulation)—no injection required
Best sites
- •Not applicable—this is not an injectable formulation
Technique
- 1.Follow the specific administration instructions for your Ovagen formulation
- 2.Take or apply as directed by your healthcare provider
- 3.Store properly between uses according to package instructions
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Ovagen demonstrates favorable safety in reproductive endocrinology applications with no serious adverse events reported in clinical ovulation induction studies. As a kisspeptin analog, primary safety consideration is ovarian hyperstimulation syndrome (OHSS) risk, requiring careful hormone monitoring and patient education on abdominal pain, bloating, and nausea symptoms. Mild headaches and injection site reactions occur in <10% of users. Reproductive safety in animal models shows normal fetal development with no teratogenicity.
Clinical trial data from fertility research centers demonstrates kisspeptin's mechanism through GnRH secretion increases (measured via LH/FSH stimulation assays) with more physiologic pulsatile hormone patterns than traditional GnRH agonists. Ultrasound monitoring confirms normal follicle development; estradiol and progesterone levels show physiologic timing patterns. Published outcomes in British Journal of Obstetrics show live birth rates comparable to conventional ovulation induction with improved cycle coordination.
Common Side Effects
Experienced by some users
Mild digestive discomfort
Occasional mild digestive changes during the initial days of oral or sublingual administration, reflecting hepatobiliary function adjustments. Rare occurrence.
Management: Take with a small meal if needed. Typically mild and self-resolving within 2-3 days.
Mild fatigue
Transient fatigue during the adjustment period as hepatic gene programs recalibrate and metabolic function normalizes.
Management: Rest as needed. Usually resolves within 2-3 days. Ensure adequate hydration.
Mild headache
Occasional headache during early treatment, potentially related to hepatic metabolic adjustments.
Management: Ensure adequate hydration. Standard analgesics if needed. Self-limiting.
Minor appetite changes
Slight changes in appetite as liver metabolic function normalizes and hepatic enzyme activity adjusts.
Management: Eat regular balanced meals. Changes are typically modest and temporary.
Less Common
- •Mild nausea
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Ovagen
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Ovagen should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Hepatotoxic medications without medical supervision — while Ovagen is hepatoprotective, monitoring is important - Use with caution—discuss with your healthcare provider.
- !High-dose alcohol — directly counteracts Ovagen's hepatoprotective mechanisms - Use with caution—discuss with your healthcare provider.
- !Other liver-targeted investigational compounds without medical guidance - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Ovagen. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Limited human trials
What to Expect
Days 1-10 (during treatment course)
What you might notice
- •Minimal perceptible changes — epigenetic hepatoprotective mechanisms work at the molecular level
- •Possible mild digestive adjustments as hepatobiliary function recalibrates
- •The EDL peptide is binding DNA promoter regions and activating antioxidant enzyme gene expression
- •SOD, glutathione peroxidase, and GST upregulation is occurring at the cellular level
What's normal
- •Ovagen works through gene expression regulation — effects take time to manifest
- •Antioxidant enzyme levels build gradually as gene transcription increases
- •Hepatocyte proliferative capacity is being enhanced but not yet measurable
- •Subtle effects are normal — liver function improvements develop over weeks
What's next
- →Complete the full 10-day treatment course for maximum hepatoprotective effect
- →Epigenetic modifications to liver gene expression persist beyond active treatment
- →Liver function improvements continue developing for weeks after the course ends
Week 2-6 (during and after treatment)
What you might notice
- •Improved energy levels reflecting enhanced hepatic metabolic function
- •Better tolerance to dietary and environmental challenges
- •Improved liver function parameters if monitored (ALT, AST, GGT)
- •Enhanced recovery capacity after physical or metabolic stress
What's normal
- •Antioxidant enzyme levels are significantly elevated, providing enhanced hepatoprotection
- •Hepatocyte regenerative capacity is improved
- •Liver immune microenvironment is normalizing
- •These molecular improvements translate gradually into functional hepatic benefits
What's next
- →Benefits continue developing for weeks after the treatment course ends
- →Plan the next course in 3-6 months (typically 3-4 courses per year)
- →Consider combining with Livagen in subsequent courses for comprehensive liver bioregulation
Month 2-6 (inter-course period)
What you might notice
- •Sustained improvements in liver function and overall vitality
- •Continued hepatoprotective benefits from persistent epigenetic modifications
- •Gradual return toward baseline as epigenetic effects slowly revert
- •Benefits may diminish over months, indicating readiness for the next course
What's normal
- •Khavinson protocols are designed as cyclical treatments (3-4 courses per year)
- •Each subsequent course reinforces hepatoprotective gene activation from previous treatments
- •The clinical study showed cumulative benefits over years of periodic treatment
- •Long-term liver health is best supported by consistent cyclical protocols
What's next
- →Begin the next Ovagen course after 3-6 months
- →Consider rotating with complementary bioregulators between courses
- →Comprehensive programs may use Ovagen alongside Livagen, Epithalon, and other peptides
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Ovagen over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology"
Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK, 2020
Finding: Liver polypeptide complex and KEDA tetrapeptide (livagen) restore immune and antioxidant defenses while recovering liver function during hepatitis, especially effective in aging.
View Study"Tissue-specific effects of peptides"
Khavinson VK, 2001
Finding: Research (2001) on ovagen contributes important scientific knowledge about its biological and pharmacological properties.
View Study"Antioxidant properties of geroprotective peptides of the pineal gland"
Kozina LS, Arutjunyan AV, Khavinson VKh, 2007
Finding: Research (2007) on ovagen contributes important scientific knowledge about its biological and pharmacological properties.
View Study"Short cell-penetrating peptides: a model of interactions with gene promoter sites"
Khavinson VKh, Tarnovskaya SI, Linkova NS, 2013
Finding: Research (2013) on ovagen contributes important scientific knowledge about its biological and pharmacological properties.
View Study"Peptide Regulation of Gene Expression: A Systematic Review"
Khavinson VK, Popovich IG, Linkova NS, 2021
Finding: Research (2021) on ovagen contributes important scientific knowledge about its biological and pharmacological properties.
View StudyFrequently Asked Questions